Techno Medical Public Co. Ltd.

Techno Medical Public Co. Ltd.

1.24
THB
-0.02
(-1.59%)
0.08EPS
9.33P/E
286.44MMarket Cap
Techno Medical Public Co. Ltd.
SET:TM.R
(Stock Exchange of Thailand)

Recent

price

1.24

P/E

ratio

9.33

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
THB
10.1
2.36
2.04
2.09
2.23
2.04
2.19
2.09
2.26
2.35
2.29
2.33
Revenue per Share
0.57
0.11
0.11
0.16
0.2
0.13
0.1
0.04
-0.01
-0.07
0.09
0.1
Basic EPS, GAAP
-1.41
-0.18
-0.15
0.24
0.46
- -
-0.17
-0.37
-0.23
1.47
1.42
1.38
Free Cash Flow per Basic Share
- -
0.56
0.01
0.08
0.1
0.13
0.1
0.08
0.05
0.03
- -
- -
Dividend per Share
0.52
1.16
1.27
1.34
1.45
1.45
1.45
1.4
1.34
1.23
1.34
1.4
Book Value per Share
0.51
1.15
1.26
1.34
1.44
1.44
1.44
1.38
1.32
1.22
1.33
1.39
Tangible Book Value per Share
51
236
308
308
308
309
308
308
308
308
308
308
Basic Weighted Avg Shares
511
556
628
644
686
631
674
643
696
725
705
717
Sales/Revenue/Turnover
9.96
7.2
7.46
9.97
10.93
9.15
8.21
2.86
0.9
-1.48
6.49
7.08
Operating Margin (%)
8
10
10
9
8
15
18
20
34
38
35
34
Depreciation Expense
29
27
35
48
61
41
30
13
-4
-22
28
31
Net Income, GAAP
21.34
12.2
19.81
20.35
19.71
21.34
34.19
34.7
- -
- -
35.45
34.47
Effective Tax Rate (%)
5.64
4.84
5.63
7.5
8.88
6.51
4.52
2.02
-0.64
-2.98
3.9
4.28
Profit Margin (%)
56
209
237
246
266
341
273
180
153
130
159
172
Working Capital
22
12
19
11
10
2
49
91
110
99
87
89
LT Debt
160
357
390
414
447
472
506
489
461
420
449
464
Total Equity
- -
7.19
6.47
8.57
9.66
6.43
4.81
1.98
- -
- -
3.94
3.98
Return on Invested Capital (%)
- -
7.36
7.22
9.07
10.54
7.31
5.04
2.5
- -
- -
5.38
5.11
Return on Capital (%)
- -
10.41
9.47
12.01
14.17
9.19
6.82
2.96
-1.06
-5.47
6.93
7.39
Return on Common Equity (%)

Capital Structure

THB

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
237
239
270
LT Borrowings
80
85
81
LT Finance Leases
7
6
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
308
308
308
Market Capitalization
311
243
286

Working Capital

THB

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
477
527
533
Cash, Cash Equivalents & STI
42
41
46
Accounts Receivable, Net
241
255
243
Inventories
148
177
192
Total Current Liabilities
318
355
360
Payables & Accruals
71
116
90
ST Debt
237
239
270
Deferred Revenue
1
- -
- -

Growth Rates

THB

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.76%
-0.82%
6.75%
Free Cash Flow
10,122.05%
20,304.1%
-3.45%
Net Income, GAAP
-0.74%
-12.47%
-227.14%
Sales/Revenue/Turnover
3.48%
2.38%
-2.76%
Total Cash Common Dividend
- -
-42.65%
-100%

Quarterly Revenue

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
180
170
193
182
725
2025
171
170
182
182
705
2026
183
171
- -
- -
- -

Quarterly Earnings Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.02
-0.02
-0.01
-0.07
2025
0.02
0.02
0.03
0.02
0.09
2026
0.03
0.03
- -
- -
- -

Quarterly Dividends Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.03
- -
- -
0.03
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Techno Medical Public Company Limited engages in the import, distribution, and trading of medical supplies, tools, and equipment primarily in Thailand. The company operates through three main segments: sales of disposable equipment and supplies including operating instruments and central sterile supply department (CSSD) products; sales of medical equipment and instruments such as diagnostic and laboratory products for laboratories and blood banks, as well as cardiovascular products and surgical tools for heart surgery; and services relating to nursing care, including the provision of nursing-care services, operation of a nursing-care school, and a small parent hospital. It also wholesales pharmaceutical products and serves government hospitals, private hospitals, clinics, and medical personnel. Founded in 2002 and headquartered at 29 Soi Ladprao 92, Phlabphla, Wangthonglang, Bangkok 10310, Thailand, the company lists on the Stock Exchange of Thailand under the ticker TM.BK. No major acquisitions, partnerships, funding rounds, new product launches, or strategic shifts have been publicly reported in the last one to two years.